Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021
July 29 2021 - 8:00AM
Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage
biopharmaceutical company focused on the development and
commercialization of transformative therapies for patients living
with central nervous system (CNS) diseases with high unmet medical
needs, today announced that it will host a virtual key opinion
leader (KOL) event to review the post triptan failure landscape and
new options for the treatment of acute migraine. In addition, the
program will cover the role of non-oral acute migraine therapies,
including the history of use of dihydroergotamine (DHE), the
STOP301 trial results for Impel’s lead product candidate TRUDHESA™
and commercial insights and opportunities in the acute migraine
market. The event will take place on Friday, August 6, 2021 at
1:00pm ET.
The event will feature presentations from guest speakers Dr.
Wade Cooper, Director of Headache and Neuropathic Pain at the
University of Michigan School of Medicine, Dr. Stewart Tepper,
Director of Dartmouth Headache Center at the Geisel School of
Medicine, Dr. Nada Hindiyeh, Assistant Professor of neurology and
neurological systems at Stanford Medical School and Impel
NeuroPharma management.
A live webcast of the event will be available on the Investors
section of the Impel NeuroPharma website at
https://investors.impelnp.com/. A replay of the webcast and
accompanying slides will be available on the Impel NeuroPharma
website following the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a late-stage
pharmaceutical company focused on utilizing its proprietary
technology to develop and commercialize transformative therapies
for people suffering from diseases with high unmet needs, with an
initial focus on diseases of the CNS. The Company’s strategy is to
rapidly advance its product candidate pipeline that pairs its
proprietary Precision Olfactory Delivery (POD®) system with
well-established therapeutics, including TRUDHESA™ for the acute
treatment of migraine, INP105 for the acute treatment of agitation
and aggression in patients with autism, and INP107 for OFF episodes
in Parkinson’s disease.
Investor Relations:Christina TartagliaStern
Investor RelationsPhone: (1)
212-362-1200Email: christina.tartaglia@sternir.com
Media Relations:Melyssa WeibleElixir Health
Public RelationsPhone: (1) 201-723-5805Email:
mweible@elixirhealthpr.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jul 2023 to Jul 2024